(Q38670012)

5 September 2017

1 reference

title

The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease (English)

1 reference

5 September 2017

1 reference

1 reference

Yan Shen

1

1 reference

5 September 2017

Xingfang Guo

2

1 reference

5 September 2017

Chao Han

3

1 reference

5 September 2017

Fang Wan

4

1 reference

5 September 2017

Kai Ma

5

1 reference

5 September 2017

Shiyi Guo

6

1 reference

5 September 2017

Luxi Wang

7

1 reference

5 September 2017

Yun Xia

8

1 reference

5 September 2017

Ling Liu

9

1 reference

5 September 2017

Zhicheng Lin

10

1 reference

5 September 2017

Jinsha Huang

11

1 reference

5 September 2017

Nian Xiong

12

1 reference

5 September 2017

Tao Wang

13

1 reference

5 September 2017

16 June 2017

1 reference

Cellular and Molecular Life Sciences

5 September 2017

1 reference

https://scigraph.springernature.com/pub.10.1007/s00018-017-2549-2

5 September 2017

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Non-motor symptoms of Parkinson's disease: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Non-motor symptoms in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Non-motor symptoms of Parkinson's disease in China: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Parkinson's disease: a review of non-motor symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Progression of non-motor symptoms in Parkinson's disease among different age populations: A two-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Neuroinflammation in Parkinson's disease: a target for neuroprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Disruption of protein quality control in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Current disease modifying approaches to treat Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Circadian rhythm dysfunction: a novel environmental risk factor for Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Inflammation as a causative factor in the aetiology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Neuroinflammation in the living brain of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Microglial phenotypes in Parkinson's disease and animal models of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Neuron-astrocyte interactions in neurodegenerative diseases: Role of neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

'The clocks that time us'--circadian rhythms in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Inflammation in Parkinson's disease: role of glucocorticoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Neuroendocrine-immune interactions and responses to exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Inflammation in neurodegenerative disease--a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Clinical review: immunomodulatory effects of dopamine in general inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

A gene atlas of the mouse and human protein-encoding transcriptomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Alpha-synuclein expression modulates microglial activation phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Genetics of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Inflammation is genetically implicated in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Parkinson's disease in the nuclear age of neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Alpha-synuclein locus duplication as a cause of familial Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

alpha-Synuclein locus triplication causes Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

A novel α-synuclein missense mutation in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Genomic investigation of alpha-synuclein multiplication and parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Receptor-interacting protein (RIP) kinase family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Genomewide association study of leprosy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Meta-analysis of published studies identified eight additional common susceptibility loci for Crohn's disease and ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Autosomal recessive parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Parkin deficiency increases vulnerability to inflammation-related nigral degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Parkinson's Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Parkin: much more than a simple ubiquitin ligase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Association of DJ-1 with chaperones and enhanced association and colocalization with mitochondrial Hsp70 by oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Regulation of astrocyte inflammatory responses by the Parkinson's disease-associated gene DJ-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The role of inflammation in sporadic and familial Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Neuroinflammation in Parkinson's disease and its potential as therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Inflammasomes and their roles in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Atp13a2 Deficiency Aggravates Astrocyte-Mediated Neuroinflammation via NLRP3 Inflammasome Activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Nurr1-Based Therapies for Parkinson's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Nurr1 expression and its modulation in microglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Involvement of induction and mitochondrial targeting of orphan nuclear receptor Nur77 in 6-OHDA-induced SH-SY5Y cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Contra-directional Coupling of Nur77 and Nurr1 in Neurodegeneration: A Novel Mechanism for Memantine-Induced Anti-inflammation and Anti-mitochondrial Impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The novel PPAR α/γ dual agonist MHY 966 modulates UVB-induced skin inflammation by inhibiting NF-κB activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

PPAR-γ: therapeutic prospects in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

A PPAR-β/δ agonist is neuroprotective and decreases cognitive impairment in a rodent model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Distribution of glucocorticoid receptor immunoreactivity and mRNA in the rat brain: an immunohistochemical and in situ hybridization study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Glucocorticoid receptor is involved in the neuroprotective effect of ginsenoside Rg1 against inflammation-induced dopaminergic neuronal degeneration in substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The molecular physiology of nuclear retinoic acid receptors. From health to disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Retinoic acid in the development, regeneration and maintenance of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Retinoic acid inhibits expression of TNF-alpha and iNOS in activated rat microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Mechanisms underlying inflammation in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Microglia-mediated neurotoxicity: uncovering the molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Microglia-Mediated Inflammation and Neurodegenerative Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Pathogen recognition and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Apoptosis-inducing factor mediates dopaminergic cell death in response to LPS-induced inflammatory stimulus: evidence in Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Microglia-Derived Cytokines/Chemokines Are Involved in the Enhancement of LPS-Induced Loss of Nigrostriatal Dopaminergic Neurons in DJ-1 Knockout Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The role of microglia in paraquat-induced dopaminergic neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Interferon-γ plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Microglia induce neural cell death via a proximity-dependent mechanism involving nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

(-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Paroxetine ameliorates lipopolysaccharide-induced microglia activation via differential regulation of MAPK signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Calorie restriction attenuates lipopolysaccharide (LPS)-induced microglial activation in discrete regions of the hypothalamus and the subfornical organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

21 January 2018

Reactive microgliosis

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Regulating factors for microglial activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Reactive microgliosis: extracellular micro-calpain and microglia-mediated dopaminergic neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Reactive microgliosis participates in MPP+-induced dopaminergic neurodegeneration: role of 67 kDa laminin receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Critical role of the Mac1/NOX2 pathway in mediating reactive microgliosis-generated chronic neuroinflammation and progressive neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Parkinson's disease: mechanisms and models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Nigrostriatal dopaminergic neurodegeneration in the weaver mouse is mediated via neuroinflammation and alleviated by minocycline administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Rotenone induces neuronal death by microglial phagocytosis of neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Rotenone and paraquat do not directly activate microglia or induce inflammatory cytokine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The immunoregulatory role of dopamine: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Close encounters of the monoamine kind: immune cells betray their nervous disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Dopamine mediates vagal modulation of the immune system by electroacupuncture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Autonomic innervation of immune organs and neuroimmune modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The inflammasome NLRs in immunity, inflammation, and associated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Suppression of neuroinflammation by astrocytic dopamine D2 receptors via αB-crystallin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Renal rescue of dopamine D2 receptor function reverses renal injury and high blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Deficient dopamine D2 receptor function causes renal inflammation independently of high blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Dopamine affects cellular immune functions during polymicrobial sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Anti-Inflammatory Effects of Acupuncture Stimulation via the Vagus Nerve

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Non-steroidal anti-inflammatory drugs in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Inflammatory dysregulation of blood monocytes in Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Parkinson's disease and prion disease: Straining the comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Intravesicular localization and exocytosis of alpha-synuclein and its aggregates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Exosomal cell-to-cell transmission of alpha synuclein oligomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Alpha-synuclein spreading in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Toll-like receptors and innate immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Exogenous α-synuclein induces toll-like receptor 4 dependent inflammatory responses in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The NALP3 inflammasome is involved in the innate immune response to amyloid-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The Nalp3 inflammasome is essential for the development of silicosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

NF-κB: emerging roles in hippocampal development and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Late-onset Parkinsonism in NFκB/c-Rel-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

NF-kappaB Signaling Pathways in Neurological Inflammation: A Mini Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Kinases and kinase signaling pathways: potential therapeutic targets in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Dopamine Autoreceptor Regulation of a Hypothalamic Dopaminergic Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Diurnal variation of hypothalamic function and chronic subthalamic nucleus stimulation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Biochemistry of the hypothalamus in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Hypothalamo-pituitary function and dopamine dependence in untreated parkinsonian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The hypothalamus in parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Microbiota-gut-brain signalling in Parkinson's disease: Implications for non-motor symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Neuropeptides and the microbiota-gut-brain axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Ghrelin-AMPK Signaling Mediates the Neuroprotective Effects of Calorie Restriction in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Acylated but not des-acyl ghrelin is neuroprotective in an MPTP mouse model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

NPY modulates PYY function in the regulation of energy balance and glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Caloric restriction stimulates autophagy in rat cortical neurons through neuropeptide Y and ghrelin receptors activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Toll-like receptors are key players in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Weight change and body composition in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Body mass index in Parkinson's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Neuroendocrine abnormalities in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Hypocretin (orexin) cell loss in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Low levels of ventricular CSF orexin/hypocretin in advanced PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Central and peripheral circadian clocks in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Circadian system - A novel diagnostic and therapeutic target in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Circadian and sleep disorders in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Dopamine and retinal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Dopamine regulates melanopsin mRNA expression in intrinsically photosensitive retinal ganglion cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Regulation of dopaminergic transmission and cocaine reward by the Clock gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Regulation of monoamine oxidase A by circadian-clock components implies clock influence on mood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

A mutation in CLOCK leads to altered dopamine receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Impact of circadian nuclear receptor REV-ERBα on midbrain dopamine production and mood regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Cocaine modulates pathways for photic and nonphotic entrainment of the mammalian SCN circadian clock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The SCN-independent clocks, methamphetamine and food restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The anti-inflammatory effect of melatonin on methamphetamine-induced proinflammatory mediators in human neuroblastoma dopamine SH-SY5Y cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Melatonin-induced autophagy protects against human prion protein-mediated neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Cognitive impairment and dementia in Parkinson's disease: practical issues and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Study of circadian melatonin secretion pattern at different stages of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Melatonin and Abnormal Movements Induced by L-Dopa in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK:BMAL1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Role of dopamine in the physiology of T-cells and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Dopamine Receptors and Neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Circadian variation in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The basic physiology and pathophysiology of melatonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Sleep and circadian rhythm regulation in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Melatonin for sleep disturbances in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Melatonin: a pleiotropic molecule regulating inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Melatonin and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Melatonin attenuates methamphetamine-induced neuroinflammation through the melatonin receptor in the SH-SY5Y cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Melatonin and brain inflammaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE/NF-K B/JNK signaling pathway in aging mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The neuroendocrine control of the circadian system: adolescent chronotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Defining the contribution of neuroinflammation to Parkinson's disease in humanized immune system mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Pioglitazone Attenuates Neuroinflammation and Promotes Dopaminergic Neuronal Survival in the Nigrostriatal System of Rats after Diffuse Brain Injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Depression and cognitive impairment in Parkinson's disease: a role for inflammation and immunomodulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Pineal melatonin functions and the depression of Parkinson's disease: a hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

The effects of pramipexole in REM sleep behavior disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Investigation on Abnormal Iron Metabolism and Related Inflammation in Parkinson Disease Patients with Probable RBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Pannexin-1-Mediated Recognition of Bacterial Molecules Activates the Cryopyrin Inflammasome Independent of Toll-like Receptor Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Weight loss in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-017-2549-2

Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude.

21 January 2018

1 reference

12 December 2020

Neural-immune interactions in health and disease

1 reference

12 December 2020

Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia

1 reference

12 December 2020

Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease

1 reference

12 December 2020

Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease.

1 reference

12 December 2020

Description of Parkinson's disease as a clinical syndrome.

1 reference

12 December 2020

Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process

1 reference

12 December 2020

The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B

1 reference

12 December 2020

Expression of circadian clock genes in retinal dopaminergic cells

1 reference

12 December 2020

Nonmotor fluctuations in Parkinson's disease: frequent and disabling

1 reference

12 December 2020

Appendectomy may delay Parkinson's disease Onset

1 reference

12 December 2020

Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study

1 reference

12 December 2020

Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1 reference

12 December 2020

The two faces of Eve: dopamine's modulation of wakefulness and sleep

1 reference

12 December 2020

Pathogenesis of Parkinson's disease

1 reference

12 December 2020

Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.

1 reference

12 December 2020

Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons.

1 reference

12 December 2020

Glucocorticoids play a fundamental role in protecting the brain during innate immune response.

1 reference

12 December 2020

Melatonin and its relation to the immune system and inflammation

1 reference

12 December 2020

Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice

1 reference

12 December 2020

The genetics of Parkinson's disease

1 reference

12 December 2020

Lack of alpha-synuclein modulates microglial phenotype in vitro

1 reference

12 December 2020

Effect of melatonin on α-synuclein self-assembly and cytotoxicity

1 reference

12 December 2020

Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor

1 reference

12 December 2020

Dopamine receptors: from structure to function

1 reference

12 December 2020

Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons.

1 reference

12 December 2020

Circadian secretion pattern of melatonin in Parkinson's disease

1 reference

12 December 2020

Melatonin prevents ischemia reperfusion injury in hamster cheek pouch microcirculation

1 reference

12 December 2020

Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen

1 reference

12 December 2020

Neuroinflammation and Parkinson disease: the silent battleground

1 reference

12 December 2020

Inflammation in Parkinson's disease: cause or consequence?

1 reference

12 December 2020

10.1007/S00018-017-2549-2

Identifiers

DOI

1 reference

5 September 2017

1 reference